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Abstract
Introduction: We performed a real-life clinical study to identify the main indications for the prescription of short-course treatment 
with systemic glucocorticosteroids (GCS) for steroid naive children with acute virus-induced wheezing as well as to analyze 
the influence of such treatment on patients’ serum cortisol level, other blood tests results and the length of stay in the hospital.
Material and methods: The data of 44 patients who had acute wheezing, had no bacterial infection and were otherwise healthy 
were analyzed: 26 children received treatment with GCS and 18 children did not. Full blood count, biochemistry tests (Na, K, 
glucose) and blood cortisol levels of all patients were analyzed during treatment.
Results: The main indications for the short-term administration of systemic GCS were increased work of breathing, recurrent 
wheezing, clinical signs of atopy and a family history of asthma. Systemic GCS increased a sodium concentration (p = 0.014), 
decreased a cortisol level (p = 0.038), leukocyte (p = 0.043), neutrophil (p = 0.045), and eosinophil (p < 0.001) count in blood 
serum. The major reduction in the eosinophil count was observed in allergic children (p = 0.023). Older age was a risk factor for 
cortisol suppression (p = 0.018). The average length of stay in the hospital was longer in the intervention group (p = 0.039). 
Conclusion: Even short-course treatment with systemic GCS decreases the serum cortisol level and has a significant effect on other blood 
tests results. Systemic GCS used for acute virus-induced wheezing treatment did not prove to reduce the average length of stay in the 
hospital. Objective criteria for initiation of such treatment are still lacking, which might consequently lead to the overuse of corticosteroids.
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Introduction
Glucocorticosteroids (GCS) are immunosup-
pressive and anti-inflammatory agents that have 
been widely used in many pediatric conditions 
for more than 60 years [1]. Respiratory diseases 
are not an exception. Acute airway obstruction 
is the most common indication for short-course 
treatment with systemic GCS [1, 2].
Current evidence recommends systemic GCS 
as an effective and safe choice for diminishing 
symptoms of asthma exacerbation and croup, but 
in clinical practice, these drugs are used more 
widely. However, their role in other respiratory 
conditions is controversial [1, 2]. To date, it rema-
ins unclear which children may benefit the most 
from systemic GCS and for whom the treatment 
is overused. Moreover, there is little evidence 
about the possible side effects of systemic GCS 
when they are given as short-course treatment for 
virus-induced wheezing in children [2, 3].
GCS can cause Cushing’s syndrome, osteopo-
rosis, arterial hypertension, growth failure, and 
obesity when they are used for a long time [3, 4]. 
The main undesirable effects occur regarding sup-
pression of the hypothalamic-pituitary-adrenal 
(HPA) axis and immune system [3, 4]. Electrolyte 
changes, hyperglycemia, cortisol suppression, 
and changes in circulating white cells are mostly 
analyzed in the adult population [4]. Their effects 
on children are still to be clarified.
Therefore, our aim was to perform a real-life 
clinical study to identify the main indications for 
prescription of short-course treatment with sys-
temic GCS for steroid naive children with acute 
virus-induced wheezing as well as to analyze the 
influence of such treatment on patients’ serum 
cortisol level, blood cells count, biochemistry 
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results and the average length of stay in the 
hospital. We hope that our results can provide 
a background for more extensive and worldwide 
investigations in this field.
Materials and methods
This prospective real-life clinical study was 
performed between February 2016 and March 
2017 in the Pediatric Department of Lithuanian 
University of Health Science Hospital (LUHSH) 
Kaunas Clinics. Approval from the institutional 
ethics committee (approval No. BEC-MF-137, 
December 15, 2015) was obtained. Parents/carers 
were provided with detailed information sheets 
and discussed the procedures with the researcher 
prior to supplying their written consent form. 
Children (1 month to 18 years old) who had 
acute wheezing, had neither bacterial infection 
nor other diseases, were included in the study. 
No patient had previously received systemic GCS 
for any reason. On admittance to the hospital, the 
clinic staff was informed about required investi-
gations and evaluation of the patient’s clinical 
signs, but no specific recommendations for tre-
atment were given to the physicians.
Age, clinical signs, family history, anamnesis 
about previous wheezing episodes and atopy, as 
well as prescribed treatment, full blood count, 
biochemistry tests (Na, K, glucose), and blood 
cortisol levels of all patients were analyzed. Re-
spiratory rate was evaluated according to the age 
of patients. Blood tests were performed on the 
first, second, and fourth days of treatment. On 
the first day of admittance, blood was drawn at 
any time before prescribed treatment, and on the 
other days, blood was drawn at 9 a.m. Systemic 
GCS were given routinely and immediately after 
the collection of blood tests. The results between 
the first and the second day and between the first 
and the fourth day were evaluated and compa-
red. Finally, we analyzed two groups of patients: 
those who received short-course treatment with 
GCS (intervention group) and those who did not 
(control group).
All blood samples were examined in the 
laboratory of LUHSH. Blood cell count was analy-
zed using an automatic hematologic analyzer 
(Sysmex XE-5000). Fluorescence flow cytometric 
analysis was performed to evaluate white blood 
cell counts and their differentials. An impedance 
method was used to calculate the platelet count. 
In some cases, the platelet count was recalcula-
ted using fluorescent reagents. A glucose level 
and sodium and potassium concentration were 
analyzed by the SYNCHRON system. The poten-
tiometric titration method was used to evaluate 
the concentration of electrolytes. The glucose 
level was estimated with the oxygen rate method 
employing a Beckman Coulter Oxygen electrode. 
Cortisol test was analyzed by ST AIA-PACK CORT. 
Competitive enzyme immunoassay method was 
used to evaluate a cortisol concentration in the 
blood plasma.
Evaluation of the cortisol level during treat-
ment was performed according to reference values 
of the cortisol concentration for all age groups 
(177–578 nmol/L in the morning, < 434 nmol/L 
in the afternoon). The change in the cortisol level 
was set after estimation of how elevated, normal, 
or decreased the cortisol values were during tre-
atment (Table 1). Because of the wide range of 
normal cortisol values, the circadian rhythm of 
the cortisol concentration, and the influence of 
possible increasing cortisol concentration factors, 
we did not use the exact cortisol concentration 
in the statistical analysis. 
Statistical analysis was performed using 
SPSS software (version 23.0). Statistical signifi-
cance was set at p < 0.05. Correlation coefficients 
were used to measure the statistical strength of 
the correlation between two variables. Spear-
Table 1. Changes in cortisol level during treatment
Level Evaluation of the change of cortisol 
2 The cortisol concentration was decreased. It increased and exceeded normal values in the blood plasma after treat-
ment
1 The cortisol concentration was decreased in the blood plasma and became normal after treatment/the cortisol concen-
tration was normal in the blood plasma and increased after treatment
0 The cortisol concentration maintained the same blood plasma level after treatment
–1 The cortisol concentration was normal in the blood plasma and decreased after treatment/the cortisol concentration 
was increased in the blood plasma and became normal after treatment
–2 The cortisol concentration was increased in the blood plasma and decreased after treatment
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Table 2. Comparison of intervention and control groups
Variable Intervention group (n = 26) Control group (n = 18) P value
Gender 8 (30.8%) female; 18 (69.2%) male 10 (55.6%) female 
8 (44.4%) male
0.091
Average age 3.4 1.8 0.08
Age group 10 (38.5%) < 2 y; 
11 (42.3%) 2–5 y; 
5 (19.2%) > 5 y
11 (61.11%) < 2 y; 
6 (33.3%) 2–5 y; 
1 (5.56%) > 5 y
0.243
Recurrent wheezing 19 (73.08%) 1 (5.56%) < 0.001
Signs of atopy 19 (73.08%) 2 (11.1%) 0.001
Usage of accessory muscles 15 (57.69%) 1 (5.56%) 0.007
Increased respiratory rate 19 (73.08%) 7 (38.89%) 0.160
Desaturation < 92% 8 (30.77%) 5 (27.77%) 0.552
Family history of asthma 8 (30.11%) 0 0.044
Leukocytes Average value before 
treatment
13.29 × 109/L 10.26 × 109/L 0.083
First day of treatment –1.5 × 109/L 1.22 × 109/L 0.043
Neutrophils Fourth day of treatment –4.27 × 109/L 0.14 × 109/L 0.045
Eosinophils First day of treatment –0.17 × 109/L 0.019 × 109/L < 0.001
Atopic children Non-atopic children 0.023
–0.18 × 109/L –0.07 × 109/L
Eosinophils Fourth day of treatment –0.15 × 109/L 0.05 × 109/L 0.007
Atopic children Non-atopic children 0.048
–0.17 × 109/L –0.003 × 109/L
Lymphocytes First day of treatment 0.2 × 109/L 1 × 109/L 0.257
Monocytes First day of treatment 0.03 × 109/L 1.5 × 109/L 0.863
Platelets First day of treatment 34.5 x 109/L 15.9 × 109/L 0.322
Sodium First day of treatment 1.69 mmol/L 0.18 mmol/L 0.014
Potassium Fourth day of treatment 0.25 mmol/L –0.08 mmol/L 0.009
Glucose First day of treatment –0.66 mmol/L –0.25 mmol/L 0.653
Cortisol level First day of treatment Maintain 
in the 
same level
Decreased 
by one 
level
Decreased 
by two 
levels
Increased 
by one 
level
Maintain 
in the 
same level
Decreased 
by one 
level
11 
(42.31%)
9  
(34.61%)
5  
(19.23%)
1  
(3.85%)
15 
(83.34%)
3  
(16.66%)
0.038
(r = 0.252)
man’s rank correlation coefficient was used for 
nonparametric variables. Pearson correlation 
coefficient was used for parametric variables. 
The Mann–Whitney test and analysis of variance 
were used for comparison of the change in rates 
between the intervention group and the control 
group. Chi2 test was used for qualitative variables.
Results
A total of 44 patients diagnosed with viral-
-induced wheezing were included in the stu-
dy: 26 children in the intervention group and 
18 children in the control group. There was no 
statistically significant difference in distribution 
by gender (p = 0.091) or age (p = 0.243) between 
the groups (Table 2). 
Methylprednisolone was applied for treat-
ment in 15 (57.7%) patients, prednisolone in 
7 (26.9%), and both drugs were used one after 
another in 4 (15.4%) patients. An average equiva-
lent dose of methylprednisolone was 1.2 mg/kg 
(min = 0.4 mg/kg, max = 2 mg/kg), and the 
average duration of administration was 4.4 days 
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Figure 1. Average age of glucocorticosteroids users in the cortisol level groups after fourth day of treatment
(min = 1 day, max = 15 days). All patients in the 
study were treated with salbutamol inhalations 
and intravenous fluids (isotonic sodium chloride 
solution). 
Recurrent wheezing, signs of atopy, a family 
history of asthma, and the use of the accessory 
muscles in breathing at rest had statistical signi-
ficance in the intervention group. There was no 
statistically significant difference in increased re-
spiratory rate or desaturation < 92% between the 
intervention and control groups (Table 2). There 
was no evidence of cyanosis in the study groups.
There was no statistically significant diffe-
rence in the initial average count of leukocytes 
in the blood between the study groups before the 
treatment (Table 2).
The decrease in leukocytes and eosinophils 
after the first day of treatment and the decrease 
in neutrophils after the fourth day of treatment 
were statistically significant in the intervention 
group (Table 2).
Signs of atopy were observed in 19 (73.08%) 
children in the intervention group, and 7 (26.92%) 
patients were nonatopic. Atopic children had 
a major reduction in the eosinophil count after 
the first day of treatment in the intervention group 
(p = 0.023), and the same effect remained after 
the fourth day as well (p = 0.048; Table 2).
There was no statistically significant differen-
ce in changes in other blood cells, such as lym-
phocytes (p = 0.257), monocytes (p = 0.863), and 
platelets (p = 0.322) during treatment (Table 2).
The sodium concentration was significantly 
higher after the first day of treatment in the in-
tervention group than in controls (Table 2). There 
was one case of hypernatremia (147 mmol/L) and 
one case of hypokalemia (3.4 mmol/L) after the 
first day of treatment in the intervention group. 
Abnormal changes in the electrolytes concen-
tration were not observed in those without GCS 
treatment.
There was no statistically significant diffe-
rence in changes in the blood plasma glucose 
level between the study groups (Table 2). Only 
one case of hyperglycemia (15.64 mmol/L) was 
registered after the first day of treatment in the 
GCS users group.
The cortisol concentration was maintained at 
the same level after the first day of treatment in 
11 (42.31%) cases, whereas it decreased by one 
level in 9 (34.62%) patients and by two levels in 
5 (19.23%) individuals treated with systemic GCS. 
There was one distinctive case in the intervention 
group in which the cortisol level increased by one 
level after the first day of GCS treatment. In this 
particular case, the cortisol concentration was 
normal and became increased in the blood plasma 
after treatment. The cortisol concentration was 
maintained at the same level in 15 cases (83.33%) 
after the first day of treatment in the control group 
and decreased by one level in 3 (16.67%) cases; 
specifically, in all 3 of these cases, the cortisol 
concentration was increased in the blood plasma 
and became normal after the first day of treatment. 
There was a statistically significant difference in 
cortisol changes after the first day of treatment 
between the study groups (r = 0.252; p = 0.038; 
Table 2). The decrease in the cortisol level in 
those who were treated with GCS was statistically 
significant after the fourth day of treatment as 
well (r = 0.262; p = 0.047). The average age of 
children was higher in the groups with a cortisol 
decrease (p = 0.018) after the fourth day of using 
systemic GCS (Figure 1). The average length of 
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stay in the hospital was significantly longer in 
the intervention group — 6.26 days, compared 
to 4.17 in the control group (p = 0.039). There 
was no statistically significant difference in the 
average length of stay in the hospital between 
allergic (6.79 days) and non-allergic (4.86 days) 
children treated with systemic GCS (p = 0.224).
Discussion 
The prevalence of asthma and other wheezing 
disorders in children is increasing worldwide [5, 6]. 
The proper diagnosis and best treatment in many 
pediatric cases is still an open question. 
It is already established that half of the chil-
dren wheeze at least once until the age of 6 years, 
but not all of them have or will have asthma, which 
is treated mainly with GCS [7, 8]. However, many 
wheezy children receive GCS for a certain period 
of time, especially during exacerbations caused by 
viral respiratory infections [1, 7–9]. Most likely, 
some of these children undergo such treatment 
without need and confirmed efficacy [7, 10]. 
Moreover, possible side effects are usually not ta-
ken into account, because it is thought that short 
courses of GCS are relatively safe [7]. Therefore, 
our aim was to analyze the existing evidence in 
the literature and to compare these data with our 
findings in a real-life clinical trial. We focused on 
indications for prescription of systemic GCS in 
children with acute virus-induced wheezing as 
well as on the clinical effects of such treatment.
Both groups in our study were conside-
red to be equal and comparable due to similar 
distribution by age and gender. We found that 
increased work of breathing at rest was the only 
significant clinical factor representing the seve-
rity of wheezing and was the main indication 
for systemic GCS prescription. The frequency of 
desaturation (SpO2 < 92%) and respiratory rate 
were similar in both study groups, and the values 
were nearly normal. Recurrent wheezing, signs 
of atopy, and a  family history of asthma were 
other significant factors found more often in the 
intervention group. 
According to the latest recommendations, 
systemic GCS are not advised for bronchiolitis but 
are strongly recommended for children with acute 
asthma exacerbation [6, 11]. Evidence supporting 
the benefits of GCS for viral-induced wheeze 
among preschool-aged children is very limited 
and conflicting [6, 9, 12]. Usually, such treatment 
is recommended and justified for children with 
severe wheezing and positive asthma predictive 
index (API), which includes a combination of 
recurrent wheezing and risk factors, such as pa-
rental history of asthma, personal history of atopic 
dermatitis, allergic sensitization to inhalant or 
food allergens, peripheral blood eosinophilia, and 
wheezing not related to a cold [8].
Our data revealed that in real life, defining 
the risk factors associated with the API is quite 
easy and could be one of the most significant 
objective indications for prescription systemic 
GCS for viral-induced wheezing, even in the 
youngest patients. This is not the case for severity 
of wheezing, however, because strict and specific 
criteria defining the level of severity and indica-
tions for the introduction of systemic GCS are 
lacking. Symptoms of a severe and life-threatening 
asthma attack are usually used for this definition 
[6]. In addition, the severity of the condition of 
a child depends on specific viral etiology or even 
multiple respiratory pathogens. Unfortunately, 
we did not find studies with evaluated systemic 
GCS effects on virus-induced wheezing caused 
by different pathogens. 
According to our results, the clinical evalu-
ation of symptom severity in real life could be 
quite complicated and more subjective rather 
than objective. We found that only one symptom, 
increased work of respiratory muscles, repre-
sented respiratory distress and was significant 
in patients treated with GCS. However, if taken 
alone, it does not always confirm severe wheezing 
and could lead to both overestimation and over-
treatment of wheezing. A better and more strict 
definition of severe wheezing is needed while 
describing indications for systemic GCS in con-
ditions other than asthma. 
Dexamethasone and prednisolone are the 
most recommended drugs for the treatment of se-
vere wheezing [1]. According to the literature, oral 
prednisolone is the steroid of choice for an asthma 
attack, but there are insufficient data about its 
safety and efficacy compared with dexamethasone 
in this situation [6]. Methylprednisolone is typi-
cally used because of its sufficient anti-inflamma-
tory properties, low mineralocorticoid, and HPA 
suppression potency [13, 14]. Methylprednisolo-
ne was the most common systemic GCS used in 
our study (57.7%). However, we cannot conclude 
that methylprednisolone was the drug of choice 
because of its superiority to other medications. 
The most possible reason is that most patients 
received methylprednisolone intravenously and 
prednisolone was given orally.
Usually, it is recommended to use pred-
nisolone or its equivalent (1–2 mg/kg) for 1 to 
5 days [1, 2]. Our results were consistent with the 
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existing recommendations, but there were still 
7 patients who were treated with systemic GCS for 
more than 5 days. Longer duration of treatment 
was related to longer hospitalization and the 
lack of treatment efficacy. It is known that geno-
mic mechanisms of GCS show effects after 4 to 
24 hours, and non-genomic effects occur even 
more rapidly [15]. The lack of efficacy after 1 to 
5 days treatment leads to a  discussion as to 
whether the GCS treatment was necessary at all. 
Therefore, we raise the idea that different 
indications and treatment options for systemic 
GCS in acute asthma and other wheezing disor-
ders should be developed. For those who have 
no asthma, it would be rational to prescribe GCS 
according to strict indications and to continue 
administration of the drug only if a positive effect 
after the first dose is observed. 
Our results showed that even a short course of 
systemic GCS decreased the leukocyte, neutrophil, 
and eosinophil counts in blood plasma. It is pro-
ven that GCS increase leukocytes [4, 16] and de-
crease lymphocytes, eosinophils, and monocytes 
in blood plasma [4]. Our study did not demonstrate 
a decrease in lymphocytes or monocytes. On the 
contrary, we found decreased levels of leukocytes 
and neutrophils in blood plasma, which were 
increased in the first blood tests. We predict that 
such changes could be found due to respiratory 
infection. In addition, any source of stress, espe-
cially the stress caused by illness, increases the 
white blood cell count and causes neutrophilia 
[17]. Therefore, the improved condition of a child 
during treatment could affect our data and cause 
a rapid decrease in inflammatory cells. 
The most common anti-inflammatory effects 
of GCS include the arrest of proliferation and 
induction of apoptosis of both T-cells and eosino-
phils [18]. It is well known that acute asthma is re-
lated to exacerbation of airway inflammation, ma-
inly caused by an increased count of eosinophils 
and their degranulation [19]. Therefore, systemic 
GCS, which cause accelerated eosinophil death, 
are strongly recommended during exacerbations 
in asthmatic patients [9]. Our results also showed 
that systemic GCS caused the most significant 
effect on the decrease of eosinophils in blood, 
but the major reduction was confirmed in allergic 
children. Most had significantly higher levels 
of eosinophils from the beginning. In line with 
other authors, we conclude that the increased 
count of eosinophils in blood could be one more 
significant indication for systemic GCS initiation 
in viral-induced wheezing when a positive effect 
could be expected [9, 19].
It is well known that systemic GCS can in-
crease a sodium concentration in blood serum: 
moderate salt-retaining properties are confirmed 
for prednisolone, and for methylprednisolone, the 
effect is lower [13]. Despite the fact that methyl-
prednisolone was the most commonly used GCS in 
our study, the increase in the sodium concentration 
in the intervention group was still significant. In 
addition, some cases of hypernatremia and hypoka-
lemia were observed and showed the risk of these 
effects for GCS users. Salbutamol and intravenous 
fluids (isotonic sodium chloride solution) were 
given to all patients, which likely could have af-
fected our data. However, no changes in sodium or 
potassium concentrations in blood were registered 
in the control group. These data suggest that all 
pediatricians should consider the risk of electrolyte 
changes if systemic GCS are prescribed.
Changes in blood glucose levels were not si-
gnificant, but there was one case of hyperglycemia 
(> 11.1 mmol/L) in the intervention group after 
the first day of treatment. More significant cases of 
hyperglycemia were observed in previous studies 
[20, 21]. Systemic GCS administration should 
be considered as a risk factor for children with 
diabetes with hyperglycemia, even if prescribed 
as a short course.
The primary results revealed an increased 
blood cortisol level in 7 children from the in-
tervention group and in 4 children from the 
control group. Previous studies analyzed the cor-
relation between the severe condition of a child 
and an increased cortisol concentration [22, 23]. 
We suspect that our findings in these particular 
children also represent the severity of symptoms 
and most likely are associated with the reaction to 
them. There was no evidence that respiratory in-
fection alone somehow affected the cortisol level.
Dora Liu et al. reported that cortisol sup-
pression is dependent on the dose and duration 
of GCS, but this relationship is more important 
for children than adults [24]. The major risk of 
adrenal suppression in adults occurs after admi-
nistration of prednisolone 20 mg (or equivalent) 
for more than 3 weeks [25], while administration 
of this drug for less than 2 weeks causes only 
a  transient decrease in the cortisol level [26]. 
These facts could not be assigned for children, 
because even relatively low doses of GCS are 
supraphysiological for them [24].  Auron and 
Raissouni in their review reported that all forms 
and methods of GCS administration can have 
a negative impact on the response of the body to 
stress, causing a lack of physiological increase of 
the cortisol level during this period [26].
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We found that the patients treated with GCS 
demonstrated a significant decrease in the cortisol 
level already after the first day of treatment. The 
results obtained on the fourth day showed the 
same effect: the cortisol level remained decreased 
for the duration of the study. Moreover, 19.23% 
of GCS users had major cortisol suppression, and 
older children were at greater risk. A previous 
study by A. Ahmet and colleagues investigated 
the direct relationship between age and adrenal 
suppression after a short course of systemic GCS 
in children, but their data were not statistically 
significant [27]. 
According to our results and previous data, 
many wheezy children in the acute period 
are prescribed systemic GCS for some days or 
weeks [1, 8, 9], but side effects of GCS given 
as short-course treatment are underestimated. 
Particular recommendations including indica-
tions, minimal effective dose, and safe duration 
for GCS prescription as short-course treatment 
are needed for the child population. It is very 
important to clarify all benefits and risks of 
systemic GCS for patients with diabetes, obese 
patients, atopic/nonatopic children, and other 
specific groups. 
According to our results, the average stay 
in the hospital was significantly longer in the 
intervention group. More severe condition of 
patients at the beginning of hospitalization might 
have influenced these findings. However, it may 
also support the idea that GCS are not effective 
to treat virus-induced wheezing, especially for 
non-asthmatic children [9–10, 12].
The main limitation of our study was the 
small number of patients and a short period of 
investigation. Moreover, patients received the 
first dose of systemic GCS at any time of day (i.e., 
when the physicians decided to prescribe them); 
therefore, the time of first blood sample varied. 
All these facts could influence our results. Also, 
because of the short time of hospitalization, we 
could not evaluate further changes in blood cor-
tisol levels after the treatment was stopped. The 
strength of the study is that it showed our needs 
and limitations in treating wheezy children in real 
life. We concentrated on a wide range of effects 
that can be caused by a short-term administration 
of systemic GCS in children. No previous similar 
clinical trials were found. Further studies are 
needed with a more precise selection of study 
groups and evaluation of both short- and long- 
-term effects of systemic GCS in different groups 
of wheezy children. 
Conclusion
Clinical signs of atopy and increased work 
of respiratory muscles, as well as a family histo-
ry of asthma and recurrence of wheezing, were 
the major indications for administration of sys-
temic GCS to wheezy children admitted to the 
hospital. The severity of wheezing was the most 
subjective and undefined variable, lacking more 
objective criteria for evaluation. Moreover, GCS 
for virus-induced wheezing did not reduce the 
length of stay in the hospital. Systemic GCS, even 
if prescribed as short-course treatment, mostly 
reduced the eosinophil count in allergic patients 
and decreased cortisol levels, especially in older 
children. Other minor effects on the levels of 
sodium, leukocytes, and neutrophils could be 
registered. 
Further studies are needed for more precise 
determination about when to start or disconti-
nue a short course of systemic GCS in wheezy 
children, especially in conditions different from 
asthma. The evaluation of risks and benefits of 
such treatment is of great importance.
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